- Home
- VALN vs MLTX Comparison
VALN vs MLTX Comparison
Compare VALN & MLTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VALN | MLTX |
|---|---|---|
| Founded | 2012 | 2021 |
| Country | France | Switzerland |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 820.0M | 979.8M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | VALN | MLTX |
|---|---|---|
| Price | $9.72 | $11.13 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 9 |
| Target Price | $15.75 | ★ $36.33 |
| AVG Volume (30 Days) | 25.2K | ★ 1.5M |
| Earning Date | 11-20-2025 | 02-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $211,089,992.00 | N/A |
| Revenue This Year | $3.64 | N/A |
| Revenue Next Year | $12.23 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 13.48 | N/A |
| 52 Week Low | $4.20 | $5.95 |
| 52 Week High | $12.25 | $62.75 |
Technical Indicators
Market Signals| Indicator | VALN | MLTX |
|---|---|---|
| Relative Strength Index (RSI) | 65.65 | 32.28 |
| Support Level | $8.77 | $11.06 |
| Resistance Level | $8.98 | $14.12 |
| Average True Range (ATR) | 0.35 | 0.74 |
| MACD | 0.14 | -0.31 |
| Stochastic Oscillator | 91.54 | 1.84 |
Price Performance
Historical ComparisonAbout VALN Valneva SE
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.
About MLTX MoonLake Immunotherapeutics
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients.